CN116854758A - Cd73抑制剂 - Google Patents

Cd73抑制剂 Download PDF

Info

Publication number
CN116854758A
CN116854758A CN202310805820.7A CN202310805820A CN116854758A CN 116854758 A CN116854758 A CN 116854758A CN 202310805820 A CN202310805820 A CN 202310805820A CN 116854758 A CN116854758 A CN 116854758A
Authority
CN
China
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310805820.7A
Other languages
English (en)
Chinese (zh)
Inventor
杜晓慧
约翰·埃克斯特洛维奇
瓦莱里娅·R·凡廷
孙大庆
叶秋萍
贾瑞德·摩尔
塔蒂亚娜·扎沃罗廷斯卡亚
布莱恩·R·布朗克
柳曜燮
吴克佳
朱柳生
约翰尼·法姆
川井弘之
叶建宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oric Pharmaceuticals Inc
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of CN116854758A publication Critical patent/CN116854758A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202310805820.7A 2019-10-30 2020-10-29 Cd73抑制剂 Pending CN116854758A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962928138P 2019-10-30 2019-10-30
US62/928,138 2019-10-30
US202062987806P 2020-03-10 2020-03-10
US62/987,806 2020-03-10
US202063088646P 2020-10-07 2020-10-07
US63/088,646 2020-10-07
PCT/US2020/057996 WO2021087136A1 (en) 2019-10-30 2020-10-29 Cd73 inhibitors
CN202080091505.7A CN114929721B (zh) 2019-10-30 2020-10-29 Cd73抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080091505.7A Division CN114929721B (zh) 2019-10-30 2020-10-29 Cd73抑制剂

Publications (1)

Publication Number Publication Date
CN116854758A true CN116854758A (zh) 2023-10-10

Family

ID=75686256

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310805820.7A Pending CN116854758A (zh) 2019-10-30 2020-10-29 Cd73抑制剂
CN202080091505.7A Active CN114929721B (zh) 2019-10-30 2020-10-29 Cd73抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080091505.7A Active CN114929721B (zh) 2019-10-30 2020-10-29 Cd73抑制剂

Country Status (19)

Country Link
US (7) US12577272B2 (cg-RX-API-DMAC7.html)
EP (2) EP4051688B1 (cg-RX-API-DMAC7.html)
JP (2) JP7544815B2 (cg-RX-API-DMAC7.html)
KR (2) KR102727229B1 (cg-RX-API-DMAC7.html)
CN (2) CN116854758A (cg-RX-API-DMAC7.html)
AU (1) AU2020375914B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159248C (cg-RX-API-DMAC7.html)
DK (1) DK4051688T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034168T3 (cg-RX-API-DMAC7.html)
FI (1) FI4051688T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072504T2 (cg-RX-API-DMAC7.html)
IL (2) IL292570B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005256A (cg-RX-API-DMAC7.html)
PL (1) PL4051688T3 (cg-RX-API-DMAC7.html)
PT (1) PT4051688T (cg-RX-API-DMAC7.html)
SI (1) SI4051688T1 (cg-RX-API-DMAC7.html)
TW (1) TWI830962B (cg-RX-API-DMAC7.html)
WO (1) WO2021087136A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204941B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CA3266927A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. PHARMACEUTICAL FORMS OF A CD73 INHIBITOR
US20240140980A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2025111247A1 (en) * 2023-11-20 2025-05-30 Oric Pharmaceuticals, Inc. Treatment of refractory multiple myeloma
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170044203A1 (en) * 2014-04-25 2017-02-16 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
US20180072742A1 (en) * 2016-09-09 2018-03-15 Lijing Chen Ectonucleotidase inhibitors and methods of use thereof
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
WO2018183635A1 (en) * 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
CN112423764A (zh) * 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
CN114929721A (zh) * 2019-10-30 2022-08-19 欧瑞克制药公司 Cd73抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023991A (en) 1911-07-29 1912-04-23 Firm B Byers Anti-rail-creeper and splice-bar.
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
LT3399984T (lt) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN111094317B (zh) 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
KR102902754B1 (ko) 2018-06-21 2025-12-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 저해제 및 이의 사용 방법
ES3053198T3 (en) 2018-08-27 2026-01-20 Arcus Biosciences Inc Cd73 inhibitors
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170044203A1 (en) * 2014-04-25 2017-02-16 Vitae Pharmaceuticals, Inc. Purine derivatives as cd73 inhibitors for the treatment of cancer
US20180072742A1 (en) * 2016-09-09 2018-03-15 Lijing Chen Ectonucleotidase inhibitors and methods of use thereof
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
WO2018183635A1 (en) * 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
CN112423764A (zh) * 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
CN114929721A (zh) * 2019-10-30 2022-08-19 欧瑞克制药公司 Cd73抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIEN AI NGUYEN等: "Chiral drugs: an riview", 《IJBS》, vol. 2, no. 2, 15 June 2006 (2006-06-15), pages 85 - 100 *

Also Published As

Publication number Publication date
CN114929721B (zh) 2023-07-18
IL292570B1 (en) 2023-12-01
US11530236B2 (en) 2022-12-20
IL308293B2 (en) 2025-12-01
EP4596048A3 (en) 2025-11-19
ES3034168T3 (en) 2025-08-13
JP7688769B2 (ja) 2025-06-04
CN114929721A (zh) 2022-08-19
JP2024164093A (ja) 2024-11-26
IL292570A (en) 2022-06-01
JP2023500483A (ja) 2023-01-06
US20210214387A1 (en) 2021-07-15
US12454544B2 (en) 2025-10-28
AU2020375914B2 (en) 2024-05-23
TW202130353A (zh) 2021-08-16
FI4051688T3 (fi) 2025-06-27
EP4051688A4 (en) 2024-03-06
EP4051688B1 (en) 2025-04-23
US20250034198A1 (en) 2025-01-30
PL4051688T3 (pl) 2025-09-22
JP7544815B2 (ja) 2024-09-03
EP4596048A2 (en) 2025-08-06
HUE072504T2 (hu) 2025-11-28
US11028120B2 (en) 2021-06-08
CA3159248C (en) 2024-05-28
KR20220088786A (ko) 2022-06-28
US20230131747A1 (en) 2023-04-27
US20210130390A1 (en) 2021-05-06
WO2021087136A1 (en) 2021-05-06
TWI830962B (zh) 2024-02-01
IL308293A (en) 2024-01-01
IL308293B1 (en) 2025-08-01
US12577272B2 (en) 2026-03-17
US20260042794A1 (en) 2026-02-12
US20220411459A1 (en) 2022-12-29
AU2020375914A1 (en) 2022-06-02
US20210130389A1 (en) 2021-05-06
BR112022008365A2 (pt) 2023-03-28
IL292570B2 (en) 2024-04-01
SI4051688T1 (sl) 2025-08-29
MX2022005256A (es) 2022-08-25
CA3159248A1 (en) 2021-05-06
EP4051688A1 (en) 2022-09-07
ZA202204941B (en) 2024-10-30
US11130778B2 (en) 2021-09-28
US12018043B2 (en) 2024-06-25
KR102727229B1 (ko) 2024-11-06
KR102653726B1 (ko) 2024-04-01
BR122023021184A2 (pt) 2024-02-27
NZ788133A (en) 2024-03-22
DK4051688T3 (da) 2025-06-30
KR20240042573A (ko) 2024-04-02
PT4051688T (pt) 2025-06-30

Similar Documents

Publication Publication Date Title
CN114929721B (zh) Cd73抑制剂
TW202014182A (zh) Cd73抑制劑
HK40079937B (zh) Cd73抑制剂
HK40079937A (en) Cd73 inhibitors
HK40096843A (zh) Cd73抑制剂
HK40081385B (en) Cd73 inhibitors
HK40081385A (en) Cd73 inhibitors
EA046660B1 (ru) Ингибиторы cd73
BR112022008365B1 (pt) Compostos inibidores de cd73, composição farmacêutica que oscompreende, método de inibição de cd73 in vitro e uso dos referidos compostos
BR122023021184B1 (pt) Compostos inibidores de cd73, composição farmacêutica que os compreende, método de inibição de cd73 in vitro e uso dos referidos compostos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096843

Country of ref document: HK